Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHF 6467

Next Previous
Search
Drug Profile

CHF 6467

Alternative Names: CHF-6467

Latest Information Update: 24 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Foot disorder therapies; Nerve growth factors
  • Mechanism of Action Nerve growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Diabetic foot ulcer

Most Recent Events

  • 20 Feb 2023 Benedetto Falsini plans phase II NGF-OPG trial in Optic nerve glioma (In adolescents, In children, In adults) in Italy in March 2023 (Ophthalmic, Drops) (NCT05733572) (CHF6467-OPG)
  • 28 Nov 2021 No recent reports of development identified for phase-I development in Diabetic-foot-ulcer in Bulgaria (Topical)
  • 07 Jan 2021 Chiesi Farmaceutici completes a phase I clinical trial in Diabetic foot ulcer in Bulgaria (Topical) (NCT04077671)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top